Friday
Sep 05
|
|
||||
|
Friday Sep 05
|
|||
| |
||||
Gates funds HIV/AIDS vaccine researchby Anshul Sood - May 20, 2007 - 1 comments
The Elizabeth Glaser Pediatric AIDS Foundation has received a five-year, $9.7-million grant from the Bill & Melinda Gates Foundation to study ways of preventing HIV/AIDS transmission to children via breast milk.
" title="Gates funds HIV/AIDS vaccine research"/> The Elizabeth Glaser Pediatric AIDS Foundation has received a five-year, $9.7-million grant from the Bill & Melinda Gates Foundation to study ways of preventing HIV/AIDS transmission to children via breast milk. The endeavor supported by the grant will be the first of its kind to support eight basic and pre-clinical research studies exploring critical questions about breast milk transmission of HIV, pediatric immune responses, identification of appropriate vaccine candidates for pediatric populations, and clinical-trial optimization. It will also support up to three Phase I clinical trials of vaccine candidates – that is, testing in a relatively small group of humans, usually healthy, to learn how the vaccines affect the body and to establish that the vaccines are generally safe. The program shall fund clinical trials utilizing products that have been safely tested on adults previously. The best products, as advised by an advisory board, will move forward. The trials shall be conducted in selective study sites complying with the highest ethical standards. The volunteers will be offered high standard care and support at that site and participants will be followed for up to two years once entering the study. Pamela W. Barnes, president and CEO of the Elizabeth Glaser Pediatric AIDS Foundation, declared that the funds will be used to develop and test candidate vaccines to prevent HIV infection in infants, noting the absence of children in HIV vaccine research even though nearly 14 percent of all new HIV infections are in children who contract the disease from their mothers and praised the Gates Foundation for making an effort on a global level to develop such a cure. "We don't want to be celebrating the discovery of an HIV vaccine and then stop and realize it's ineffective or unsafe for children," she said in a foundation statement issued about the grant. "We need research aimed at both children and adults and the Gates Foundation is helping make that possible." Barnes briefs the presence of only two vaccine trials aimed at blocking transmission of the virus from mother-to-child, either during childbirth or through breast-feeding and those infected by latter are certainly in a better position to benefit from a preventative vaccine dosed shortly after birth and may also be able to gain immunity from the virus for life. “Vaccinating children has been the key to tackling the world’s deadliest epidemics, and HIV could be the next chapter in that story,” said Barnes. “It is absolutely vital that we start to include children in HIV vaccine research, or we may miss important discoveries that only pediatric research could reveal.”, she added. Elizabeth Glaser Pediatric AIDS Foundation has been active in this field since 1988, providing $10 million to support 41 separate studies related to pediatric vaccine research. The new grant aims at expanding EGPAF’s ability to fund critical vaccine research and is nearly equal to all the money the Glaser Foundation spent on HIV/AIDS research between 1988 and 2007. The EGPAF mainly focuses on rigorous research in the field of pediatric HIV/AIDS in order to slow HIV infection in children, prevent new infections, develop a preventative vaccine and ultimately finding a cure for HIV/AIDS. The Gates Foundation, created in 2000 in Seattle, Washington by Bill and Melinda Gates, is the largest transparently operated charitable foundation in the world and was doubled in size by Warren Buffet in 2006. It has spent nearly $500 million on initiatives to prevent the spread of HIV and for research into potential HIV/AIDS vaccines. It also has spent millions of dollars to reduce extreme poverty, and, in the United States, to expand educational opportunities and access to information technology. In 2006, more than 500,000 children contracted HIV — most as a result of mother-to-child transmission of the virus and one in three cases are estimated to occur through breast feeding. According to researchers, there is a need to study a vaccine in a pediatric population as they work differently in adult and children’s bodies. The recently published malaria vaccine trials conducted by GlaxoSmithkline showed better efficacy of the vaccine in one- to four-year-olds than in adults. Also, other vaccines already in use require fewer doses in children than adults to generate the same level of protection. Examples include Hepatitis B, chickenpox, and HPV vaccines. |
|
||||||
Disclaimer: The views and investment tips expressed by investment experts on themoneytimes.com are their own, and not that of the website or its management. TheMoneyTimes advises users to check with certified experts before taking any investment decision. ©2004-2008 All Rights Reserved unless mentioned otherwise. [Submit News/Press Release][Terms of Service] [Privacy Policy] [About us] [Contact us] |
HIV Now Under Attack by an Oral AIDS Vaccine Named Immureboost
Tue Jun 5, 10:40 AM ET
Vichai Jirathitikal has developed an oral
AIDS vaccine originally named V-1. V1 is a specially formulated pill that contains
HIV-1 viral antigens capable of withstanding the degradation in the stomach. As a result V1 can pass into the gastrointestinal tract and will be eventually presented by intestinal enterocytes to underlying mucosal immune cells.
Bangkok, Thailand (PRWEB) June 6, 2007 -- Mr. Vichai Jirathitikal, a pharmacology graduate of Mahidol University, has developed an oral AIDS vaccine originally named V-1 or V1.V1 comprises pooled, inactivated HIV antigens derived from E and B clades of HIV-1 strain predominant in Thai population and is currently manufactured at a pharmaceutical plant owned by his family. The factory received GMP status form Thai FDA in July 2001. In contrast to other AIDS vaccines V1 is administered orally and not by injection.
V1 is a specially formulated pill that contains HIV-1 viral antigens capable of withstanding the degradation in the stomach. As a result V1 can pass into the gastrointestinal tract and will be eventually presented by intestinal enterocytes to underlying mucosal immune cells. The V1 is presented as 850mg pink-colored oval shaped pill. Vaccine is stable at ambient temperature for more than a year.
In the last few years Pharmacist Vichai has treated about 500 HIV-positive patients at his clinic in Bangpakong - a place located about 40 minutes drive from Bangkok City. When news of V1 therapy became known to the public the demand surged to unprecedented levels. Starting from June 2001 V1-Immunitor was distributed free of charge to about 40 thousand of HIV-infected individuals.The distribution was primarily sponsored by Immureboost Corporation.
V-1 is the most advanced product that has been used by over 66,000 thousand AIDS patients in more than 60 countries around the world. In a recent clinical study V-1 has normalized elevated liver enzymes in 95% of treated patients within one month, meaning that V-1 is potentially effective for hepatitis treatment (the article describing the clinical data was published in April, 2003 issue of Electronic Journal of Biotechnology - peer-reviewed journal sponsored by UNSECO). Considering that hepatitis is a poorly treatable disease that affects 500 million people, mostly in Asian countries, V-1 represents a considerable commercial value with return on investment potential vastly superior to AIDS, a disease which affects over 40 million people, most of whom are in low-income African countries.
V-1 was the first product developed by Mr. Vichai Jirathitikal. He now has other products of V-series which are all licensed by the Thai FDA as food supplements. V-2 is a broad spectrum anti-bacterial product, V-4 is anti-fungal product, and V-3 is an anti-cancer and is all available as pills. V-1 comprises pooled, inactivated HIV antigens derived from E and B clades of HIV-1 strain predominant in Thai population and is currently manufactured at a pharmaceutical plant owned by his family as an oral pill to be given to HIV-positive patients.
Situation in Thailand
Thailand has approximately one million people with HIV. While preventive measures established by the Government of Thailand are effective, the financial burden of caring for HIV/AIDS patients is beyond the budgetary means of the country, especially if 30 baht insurance program will be covering HIV-positive individuals. The Thai government is capable to provide free treatment for only 2,500 patients per year. The overwhelming majority of Thai HIV/AIDS patients have no access to antiretroviral drugs that have reduced death rates in Western countries. Antivirals even at subsidized prices are beyond of reach to ordinary Thais. At currently announced 1,800 baht (~$50US) per month the price of generic antiviral to be produced by the Government Pharmaceutical Organization of Thailand is still too high for most patients. Hospitals routinely send patients with terminal, full-blown AIDS to Buddhist temples to die. Unless something is done in expedite manner the situation in Thailand is extremely serious.
After more then ten years of intense laboratory studies and donating his time and money, Mr. Vichai Jirathitikal is now finalizing negotiations with a NASDAQ BB company who will make his dream come true. "Saving lives is so important Mr. Vichai exclaimed and we need money to build the laboratories for worldwide distribution of the V1 product". Immureboost (www.immureboost.com) has entered into an agreement with E savings store or (esav.ob) this company will help raise money to build manufacturing plants and labs globally to help people who are suffering from the HIV virus. Immureboost until several months ago was struggling until they hired a new consulting firm named e commerce energy (www.e-commerce-energy.com ) this company has helped them to develop their web site and connect them with different countries around the world so the V1 product would be exposed and recognized for a new miracle for people with AIDS.
###
immureboost
Vichai Jirathitikal
+6626927844
E-mail Information